The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo

E. S. Hwang, J. Kim, J. S. Kim, Chinghai Kao, S. C. Ko, L. Chung, J. H. Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The effect of p53 overexpression on the proliferation of various ovarian cancer cell lines was tested by using an adenovirus vector, Avp53, that expresses wild-type human p53. Cell lines SKOV3, 2774, and OVCAR3, which bear mutations in the endogenous p53 gene, were all affected by Avp53 treatment, undergoing growth suppression and apoptosis at a dose that had little effect on the growth of normal fibroblasts. In these cells, p21WAF1/CIP1 was readily induced and the hypophosphorylated pRb protein accumulated by the treatment of Avp53, suggesting that the growth inhibitory pathway can be activated in these cells by the expression of wild-type p53. However, in PA-1 cell line which endogenously expresses wild-type p53, p21WAF1/CIP1 was not induced by p53 transduction, although p53 was found transcriptionally active. These results indicate that the tested ovarian cancer cell lines bear defects either in p53 itself or in the responsiveness to p53. The cytocidal effect of Avp53 was also examined in vivo against tumors developed in the peritoneal cavity of nude mice. Avp53 administered intraperitoneally eradicated microscopic and small-sized tumor nodules, demonstrating that the intraperitoneal administration of Avp53 may serve as an effective adjuvant therapy for ovarian cancers.

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalInternational Journal of Gynecological Cancer
Volume8
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Adenoviridae
Ovarian Neoplasms
Cell Line
Growth
p53 Genes
Peritoneal Cavity
Nude Mice
Neoplasms
Fibroblasts
Apoptosis
Mutation
In Vitro Techniques
Ovarian epithelial cancer
Proteins
Therapeutics

Keywords

  • Apoptosis
  • Cancer gene therapy
  • Growth suppression
  • P21WAF1/CIP1
  • P53
  • PRb

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo. / Hwang, E. S.; Kim, J.; Kim, J. S.; Kao, Chinghai; Ko, S. C.; Chung, L.; Lee, J. H.

In: International Journal of Gynecological Cancer, Vol. 8, No. 1, 1998, p. 27-36.

Research output: Contribution to journalArticle

@article{95df2eaae61a4a73b0b94a8238a2835a,
title = "The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo",
abstract = "The effect of p53 overexpression on the proliferation of various ovarian cancer cell lines was tested by using an adenovirus vector, Avp53, that expresses wild-type human p53. Cell lines SKOV3, 2774, and OVCAR3, which bear mutations in the endogenous p53 gene, were all affected by Avp53 treatment, undergoing growth suppression and apoptosis at a dose that had little effect on the growth of normal fibroblasts. In these cells, p21WAF1/CIP1 was readily induced and the hypophosphorylated pRb protein accumulated by the treatment of Avp53, suggesting that the growth inhibitory pathway can be activated in these cells by the expression of wild-type p53. However, in PA-1 cell line which endogenously expresses wild-type p53, p21WAF1/CIP1 was not induced by p53 transduction, although p53 was found transcriptionally active. These results indicate that the tested ovarian cancer cell lines bear defects either in p53 itself or in the responsiveness to p53. The cytocidal effect of Avp53 was also examined in vivo against tumors developed in the peritoneal cavity of nude mice. Avp53 administered intraperitoneally eradicated microscopic and small-sized tumor nodules, demonstrating that the intraperitoneal administration of Avp53 may serve as an effective adjuvant therapy for ovarian cancers.",
keywords = "Apoptosis, Cancer gene therapy, Growth suppression, P21WAF1/CIP1, P53, PRb",
author = "Hwang, {E. S.} and J. Kim and Kim, {J. S.} and Chinghai Kao and Ko, {S. C.} and L. Chung and Lee, {J. H.}",
year = "1998",
doi = "10.1046/j.1525-1438.1998.09772.x",
language = "English (US)",
volume = "8",
pages = "27--36",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo

AU - Hwang, E. S.

AU - Kim, J.

AU - Kim, J. S.

AU - Kao, Chinghai

AU - Ko, S. C.

AU - Chung, L.

AU - Lee, J. H.

PY - 1998

Y1 - 1998

N2 - The effect of p53 overexpression on the proliferation of various ovarian cancer cell lines was tested by using an adenovirus vector, Avp53, that expresses wild-type human p53. Cell lines SKOV3, 2774, and OVCAR3, which bear mutations in the endogenous p53 gene, were all affected by Avp53 treatment, undergoing growth suppression and apoptosis at a dose that had little effect on the growth of normal fibroblasts. In these cells, p21WAF1/CIP1 was readily induced and the hypophosphorylated pRb protein accumulated by the treatment of Avp53, suggesting that the growth inhibitory pathway can be activated in these cells by the expression of wild-type p53. However, in PA-1 cell line which endogenously expresses wild-type p53, p21WAF1/CIP1 was not induced by p53 transduction, although p53 was found transcriptionally active. These results indicate that the tested ovarian cancer cell lines bear defects either in p53 itself or in the responsiveness to p53. The cytocidal effect of Avp53 was also examined in vivo against tumors developed in the peritoneal cavity of nude mice. Avp53 administered intraperitoneally eradicated microscopic and small-sized tumor nodules, demonstrating that the intraperitoneal administration of Avp53 may serve as an effective adjuvant therapy for ovarian cancers.

AB - The effect of p53 overexpression on the proliferation of various ovarian cancer cell lines was tested by using an adenovirus vector, Avp53, that expresses wild-type human p53. Cell lines SKOV3, 2774, and OVCAR3, which bear mutations in the endogenous p53 gene, were all affected by Avp53 treatment, undergoing growth suppression and apoptosis at a dose that had little effect on the growth of normal fibroblasts. In these cells, p21WAF1/CIP1 was readily induced and the hypophosphorylated pRb protein accumulated by the treatment of Avp53, suggesting that the growth inhibitory pathway can be activated in these cells by the expression of wild-type p53. However, in PA-1 cell line which endogenously expresses wild-type p53, p21WAF1/CIP1 was not induced by p53 transduction, although p53 was found transcriptionally active. These results indicate that the tested ovarian cancer cell lines bear defects either in p53 itself or in the responsiveness to p53. The cytocidal effect of Avp53 was also examined in vivo against tumors developed in the peritoneal cavity of nude mice. Avp53 administered intraperitoneally eradicated microscopic and small-sized tumor nodules, demonstrating that the intraperitoneal administration of Avp53 may serve as an effective adjuvant therapy for ovarian cancers.

KW - Apoptosis

KW - Cancer gene therapy

KW - Growth suppression

KW - P21WAF1/CIP1

KW - P53

KW - PRb

UR - http://www.scopus.com/inward/record.url?scp=0031909642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031909642&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.1998.09772.x

DO - 10.1046/j.1525-1438.1998.09772.x

M3 - Article

VL - 8

SP - 27

EP - 36

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -